Market news

This biotech has grabbed plenty of headlines recently.

Intellia update: Claude AI flags a gene-editing setup but can’t replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.

Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.

Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

Intellia Therapeutics (NTLA) has spent years being valued as a gene-editing science project.

I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Intellia Therapeutics (NTLA).

Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

Intellia Therapeutics (NTLA) stock gains on FDA priority review for lonvo-z, a gene editing therapy for a rare condition called hereditary angioedema. Read more here.

Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.

Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has accepted the

Intellia Therapeutics (NTLA) stock is in focus after the company arranged a $400 million non dilutive senior secured term loan facility with OrbiMed to support lonvoguran ziclumeran, or lonvo z, development and launch plans. The financing news comes after a mixed period for Intellia Therapeutics. The share price is US$12.74, with a 30-day share price return of 16.13%, but the 3-year total shareholder return has declined 66.36% and the 5-year total shareholder return has declined 92.07%. Scan...

Intellia Therapeutics recently entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, with full details to follow in an SEC Form 8-K filing. This financing structure, which ties most of the available capital to lonvo-z development milestones, highlights how central that program has become to Intellia’s funding...

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an agg

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET. A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’

Intellia Therapeutics (NTLA) entered a $400 million non-dilutive senior secured term loan facility w

Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Moby summary of Intellia Therapeutics, Inc.'s Q2 2026 earnings call

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes fo

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should d